Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® - GlobeNewswire

August 25, 2019

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® GlobeNewswire

JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal ...

Signs of Pulmonary Embolism

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® - GlobeNewswire

Comments

Post a Comment

Popular posts from this blog

Investigational oral contraceptive patch offers comparable safety to approved products - Healio

EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns - Endpoints News

What Caused Young IBD Patient's Headache and Right-Side Weakness? - MedPage Today